Sonja J. McKeown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sonja J. McKeown has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Heather M. Young
University of Melbourne
11 shared publications - Lincon A. Stamp
Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC, Australia
6 shared publications - Joel Charles Bornstein
Department of Anatomy and Physiology, University of Melbourne, Parkville Vic, 3010, Australia
5 shared publications - Marianne Bronner-Fraser
Division of Biology and Biological Engineering, California Institute of Technology
5 shared publications - Marlene M. Hao
Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC, Australia
5 shared publications Aparna Jayachandran
Olivia Newton-John Cancer Research Institute, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Victoria, Australia
4 shared publications
Latest Publications
- 25 April 2025
- Published by Elsevier in Developmental Biology
- Vol. 524, 29-35
Inclusion of planetary health in developmental biology education
- 25 April 2025
- Published by Elsevier in Developmental Biology
- Vol. 524, 29-35
Inclusion of planetary health in developmental biology education
- Open Access
- 30 October 2022
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (3) , 269-280
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease
Individuals diagnosed with neurodevelopmental conditions such as autism spectrum disorder (ASD; autism) often experience tissue inflammation as well as gastrointestinal dysfunction, yet their underlying causes remain poorly characterised. Notably, the largest components of the body’s immune system, including gut-associated lymphoid tissue (GALT), lie within the gastrointestinal tract. A major constituent of GALT in humans comprises secretory lymphoid aggregates known as Peyer’s patches that sense and combat constant exposure to pathogens and infectious agents. Essential to the functions of Peyer’s patches is its communication with the enteric nervous system (ENS), an intrinsic neural network that regulates gastrointestinal function. Crosstalk between these tissues contribute to the microbiota-gut-brain axis that altogether influences mood and behaviour. Increasing evidence further points to a critical role for this signalling axis in neurodevelopmental homeostasis and disease. Notably, while the neuroimmunomodulatory functions for Peyer’s patches are increasingly better understood, functions for tissues of analogous function, such as caecal patches, remain less well characterised. Here, we compare the structure, function and development of Peyer’s patches, as well as caecal and appendix patches in humans and model organisms including mice to highlight the roles for these essential tissues in health and disease. We propose that perturbations to GALT function may underlie inflammatory disorders and gastrointestinal dysfunction in neurodevelopmental conditions such as autism.
- 30 October 2022
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (3) , 269-280
Open AccessIssues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease
Individuals diagnosed with neurodevelopmental conditions such as autism spectrum disorder (ASD; autism) often experience tissue inflammation as well as gastrointestinal dysfunction, yet their underlying causes remain poorly characterised. Notably, the largest components of the body’s immune system, including gut-associated lymphoid tissue (GALT), lie within the gastrointestinal tract. A major constituent of GALT in humans comprises secretory lymphoid aggregates known as Peyer’s patches that sense and combat constant exposure to pathogens and infectious agents. Essential to the functions of Peyer’s patches is its communication with the enteric nervous system (ENS), an intrinsic neural network that regulates gastrointestinal function. Crosstalk between these tissues contribute to the microbiota-gut-brain axis that altogether influences mood and behaviour. Increasing evidence further points to a critical role for this signalling axis in neurodevelopmental homeostasis and disease. Notably, while the neuroimmunomodulatory functions for Peyer’s patches are increasingly better understood, functions for tissues of analogous function, such as caecal patches, remain less well characterised. Here, we compare the structure, function and development of Peyer’s patches, as well as caecal and appendix patches in humans and model organisms including mice to highlight the roles for these essential tissues in health and disease. We propose that perturbations to GALT function may underlie inflammatory disorders and gastrointestinal dysfunction in neurodevelopmental conditions such as autism.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2)
Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes
Huntington’s disease is characterised by a triad of motor, cognitive, and psychiatric impairments, as well as unintended weight loss. Although much of the research has focused on cognitive, motor and psychiatric symptoms, the extent of peripheral pathology and the relationship between these factors, and the core symptoms of Huntington’s disease, are relatively unknown. Gut microbiota are key modulators of communication between the brain and gut, and alterations in microbiota composition (dysbiosis) can negatively affect cognition, behaviour and affective function, and may be implicated in disease progression. Furthermore, gut dysbiosis was recently reported in Huntington’s disease transgenic mice. Our main objective was to characterise the gut microbiome in people with Huntington’s disease and determine whether the composition of gut microbiota are significantly related to clinical indicators of disease progression. We compared 42 Huntington’s disease gene expansion carriers (HDGECs), including 19 people who were diagnosed with Huntington’s disease (Total Functional Capacity > 6) and 23 in the premanifest stage, with 36 age and gender-matched healthy controls. Participants were characterised clinically using a battery of cognitive tests and using results from 16S V3-V4 rRNA sequencing of faecal samples to characterise the gut microbiome. For gut microbiome measures, we found significant differences in the microbial communities (beta diversity) based on unweighted UniFrac distance (p = 0.001), as well as significantly lower alpha diversity (species richness and evenness) between our combined HDGEC group and healthy controls (p = 0.001). We also found major shifts in the microbial community structure at Phylum and Family levels, and identified functional pathways and enzymes affected in our HDGEC group. Within the HDGEC group, we also discovered associations between gut bacteria, cognitive performance and clinical outcomes. Overall, our findings suggest an altered gut microbiome in HDGECs. These results highlight the importance of gut biomarkers and raise interesting questions regarding the role of the gut in Huntington’s disease, and whether it may be a potential target for future therapeutic intervention.
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2)
Open AccessGut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes
Huntington’s disease is characterised by a triad of motor, cognitive, and psychiatric impairments, as well as unintended weight loss. Although much of the research has focused on cognitive, motor and psychiatric symptoms, the extent of peripheral pathology and the relationship between these factors, and the core symptoms of Huntington’s disease, are relatively unknown. Gut microbiota are key modulators of communication between the brain and gut, and alterations in microbiota composition (dysbiosis) can negatively affect cognition, behaviour and affective function, and may be implicated in disease progression. Furthermore, gut dysbiosis was recently reported in Huntington’s disease transgenic mice. Our main objective was to characterise the gut microbiome in people with Huntington’s disease and determine whether the composition of gut microbiota are significantly related to clinical indicators of disease progression. We compared 42 Huntington’s disease gene expansion carriers (HDGECs), including 19 people who were diagnosed with Huntington’s disease (Total Functional Capacity > 6) and 23 in the premanifest stage, with 36 age and gender-matched healthy controls. Participants were characterised clinically using a battery of cognitive tests and using results from 16S V3-V4 rRNA sequencing of faecal samples to characterise the gut microbiome. For gut microbiome measures, we found significant differences in the microbial communities (beta diversity) based on unweighted UniFrac distance (p = 0.001), as well as significantly lower alpha diversity (species richness and evenness) between our combined HDGEC group and healthy controls (p = 0.001). We also found major shifts in the microbial community structure at Phylum and Family levels, and identified functional pathways and enzymes affected in our HDGEC group. Within the HDGEC group, we also discovered associations between gut bacteria, cognitive performance and clinical outcomes. Overall, our findings suggest an altered gut microbiome in HDGECs. These results highlight the importance of gut biomarkers and raise interesting questions regarding the role of the gut in Huntington’s disease, and whether it may be a potential target for future therapeutic intervention.
- Open Access
- 22 May 2019
- Published by Wiley in Autism Research
- Vol. 12 (7) , 1043-1056
Gastrointestinal dysfunction in patients and mice expressing the autism‐associated R451C mutation in neuroligin‐3
Gastrointestinal (GI) problems constitute an important comorbidity in many patients with autism. Multiple mutations in the neuroligin family of synaptic adhesion molecules are implicated in autism, however whether they are expressed and impact GI function via changes in the enteric nervous system is unknown. We report the GI symptoms of two brothers with autism and an R451C mutation in Nlgn3 encoding the synaptic adhesion protein, neuroligin‐3. We confirm the presence of an array of synaptic genes in the murine GI tract and investigate the impact of impaired synaptic protein expression in mice carrying the human neuroligin‐3 R451C missense mutation (NL3R451C). Assessing in vivo gut dysfunction, we report faster small intestinal transit in NL3R451C compared to wild‐type mice. Using an ex vivo colonic motility assay, we show increased sensitivity to GABAA receptor modulation in NL3R451C mice, a well‐established Central Nervous System (CNS) feature associated with this mutation. We further show increased numbers of small intestine myenteric neurons in NL3R451C mice. Although we observed altered sensitivity to GABAA receptor modulators in the colon, there was no change in colonic neuronal numbers including the number of GABA‐immunoreactive myenteric neurons. We further identified altered fecal microbial communities in NL3R451C mice. These results suggest that the R451C mutation affects small intestinal and colonic function and alter neuronal numbers in the small intestine as well as impact fecal microbes. Our findings identify a novel GI phenotype associated with the R451C mutation and highlight NL3R451C mice as a useful preclinical model of GI dysfunction in autism. Autism Res 2019, 12: 1043–1056. © 2019 International Society for Autism Research, Wiley Periodicals, Inc.Lay Summary: People with autism commonly experience gastrointestinal problems, however the cause is unknown. We report gut symptoms in patients with the autism‐associated R451C mutation encoding the neuroligin‐3 protein. We show that many of the genes implicated in autism are expressed in mouse gut. The neuroligin‐3 R451C mutation alters the enteric nervous system, causes gastrointestinal dysfunction, and disrupts gut microbe populations in mice. Gut dysfunction in autism could be due to mutations that affect neuronal communication.
- 22 May 2019
- Published by Wiley in Autism Research
- Vol. 12 (7) , 1043-1056
Open AccessGastrointestinal dysfunction in patients and mice expressing the autism‐associated R451C mutation in neuroligin‐3
Gastrointestinal (GI) problems constitute an important comorbidity in many patients with autism. Multiple mutations in the neuroligin family of synaptic adhesion molecules are implicated in autism, however whether they are expressed and impact GI function via changes in the enteric nervous system is unknown. We report the GI symptoms of two brothers with autism and an R451C mutation in Nlgn3 encoding the synaptic adhesion protein, neuroligin‐3. We confirm the presence of an array of synaptic genes in the murine GI tract and investigate the impact of impaired synaptic protein expression in mice carrying the human neuroligin‐3 R451C missense mutation (NL3R451C). Assessing in vivo gut dysfunction, we report faster small intestinal transit in NL3R451C compared to wild‐type mice. Using an ex vivo colonic motility assay, we show increased sensitivity to GABAA receptor modulation in NL3R451C mice, a well‐established Central Nervous System (CNS) feature associated with this mutation. We further show increased numbers of small intestine myenteric neurons in NL3R451C mice. Although we observed altered sensitivity to GABAA receptor modulators in the colon, there was no change in colonic neuronal numbers including the number of GABA‐immunoreactive myenteric neurons. We further identified altered fecal microbial communities in NL3R451C mice. These results suggest that the R451C mutation affects small intestinal and colonic function and alter neuronal numbers in the small intestine as well as impact fecal microbes. Our findings identify a novel GI phenotype associated with the R451C mutation and highlight NL3R451C mice as a useful preclinical model of GI dysfunction in autism. Autism Res 2019, 12: 1043–1056. © 2019 International Society for Autism Research, Wiley Periodicals, Inc.Lay Summary: People with autism commonly experience gastrointestinal problems, however the cause is unknown. We report gut symptoms in patients with the autism‐associated R451C mutation encoding the neuroligin‐3 protein. We show that many of the genes implicated in autism are expressed in mouse gut. The neuroligin‐3 R451C mutation alters the enteric nervous system, causes gastrointestinal dysfunction, and disrupts gut microbe populations in mice. Gut dysfunction in autism could be due to mutations that affect neuronal communication.
- Open Access
- 8 June 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 9085
Publisher Correction: Kif1bp loss in mice leads to defects in the peripheral and central nervous system and perinatal death
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
- 8 June 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 9085
Open AccessPublisher Correction: Kif1bp loss in mice leads to defects in the peripheral and central nervous system and perinatal death
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
- Open Access
- 30 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 16676
Kif1bp loss in mice leads to defects in the peripheral and central nervous system and perinatal death
Goldberg-Shprintzen syndrome is a poorly understood condition characterized by learning difficulties, facial dysmorphism, microcephaly, and Hirschsprung disease. GOSHS is due to recessive mutations in KIAA1279, which encodes kinesin family member 1 binding protein (KIF1BP, also known as KBP). We examined the effects of inactivation of Kif1bp in mice. Mice lacking Kif1bp died shortly after birth, and exhibited smaller brains, olfactory bulbs and anterior commissures, and defects in the vagal and sympathetic innervation of the gut. Kif1bp was found to interact with Ret to regulate the development of the vagal innervation of the stomach. Although newborn Kif1bp−/− mice had neurons along the entire bowel, the colonization of the gut by neural crest-derived cells was delayed. The data show an essential in vivo role for KIF1BP in axon extension from some neurons, and the reduced size of the olfactory bulb also suggests additional roles for KIF1BP. Our mouse model provides a valuable resource to understand GOSHS.
- 30 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 16676
Open AccessKif1bp loss in mice leads to defects in the peripheral and central nervous system and perinatal death
Goldberg-Shprintzen syndrome is a poorly understood condition characterized by learning difficulties, facial dysmorphism, microcephaly, and Hirschsprung disease. GOSHS is due to recessive mutations in KIAA1279, which encodes kinesin family member 1 binding protein (KIF1BP, also known as KBP). We examined the effects of inactivation of Kif1bp in mice. Mice lacking Kif1bp died shortly after birth, and exhibited smaller brains, olfactory bulbs and anterior commissures, and defects in the vagal and sympathetic innervation of the gut. Kif1bp was found to interact with Ret to regulate the development of the vagal innervation of the stomach. Although newborn Kif1bp−/− mice had neurons along the entire bowel, the colonization of the gut by neural crest-derived cells was delayed. The data show an essential in vivo role for KIF1BP in axon extension from some neurons, and the reduced size of the olfactory bulb also suggests additional roles for KIF1BP. Our mouse model provides a valuable resource to understand GOSHS.
- 28 May 2017
- Published by Springer Nature
- Vol. 224, 159-187
Extracerebral Dysfunction in Animal Models of Autism Spectrum Disorder
Genetic factors might be largely responsible for the development of autism spectrum disorder (ASD) that alone or in combination with specific environmental risk factors trigger the pathology. Multiple mutations identified in ASD patients that impair synaptic function in the central nervous system are well studied in animal models. How these mutations might interact with other risk factors is not fully understood though. Additionally, how systems outside of the brain are altered in the context of ASD is an emerging area of research. Extracerebral influences on the physiology could begin in utero and contribute to changes in the brain and in the development of other body systems and further lead to epigenetic changes. Therefore, multiple recent studies have aimed at elucidating the role of gene-environment interactions in ASD. Here we provide an overview on the extracerebral systems that might play an important associative role in ASD and review evidence regarding the potential roles of inflammation, trace metals, metabolism, genetic susceptibility, enteric nervous system function and the microbiota of the gastrointestinal (GI) tract on the development of endophenotypes in animal models of ASD. By influencing environmental conditions, it might be possible to reduce or limit the severity of ASD pathology.
- 28 May 2017
- Published by Springer Nature
- Vol. 224, 159-187
Extracerebral Dysfunction in Animal Models of Autism Spectrum Disorder
Genetic factors might be largely responsible for the development of autism spectrum disorder (ASD) that alone or in combination with specific environmental risk factors trigger the pathology. Multiple mutations identified in ASD patients that impair synaptic function in the central nervous system are well studied in animal models. How these mutations might interact with other risk factors is not fully understood though. Additionally, how systems outside of the brain are altered in the context of ASD is an emerging area of research. Extracerebral influences on the physiology could begin in utero and contribute to changes in the brain and in the development of other body systems and further lead to epigenetic changes. Therefore, multiple recent studies have aimed at elucidating the role of gene-environment interactions in ASD. Here we provide an overview on the extracerebral systems that might play an important associative role in ASD and review evidence regarding the potential roles of inflammation, trace metals, metabolism, genetic susceptibility, enteric nervous system function and the microbiota of the gastrointestinal (GI) tract on the development of endophenotypes in animal models of ASD. By influencing environmental conditions, it might be possible to reduce or limit the severity of ASD pathology.
- Open Access
- 1 February 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (2) , 476-488
Exposure to GDNF Enhances the Ability of Enteric Neural Progenitors to Generate an Enteric Nervous System
- 1 February 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (2) , 476-488
Open AccessExposure to GDNF Enhances the Ability of Enteric Neural Progenitors to Generate an Enteric Nervous System
- 6 July 2016
- Published by Springer Nature
- Vol. 891, 53-62
ENS Development Research Since 1983: Great Strides but Many Remaining Challenges
The first enteric nervous system (ENS) conference, organized by Marcello Costa and John Furness, was held in Adelaide, Australia in 1983. In this article, we review what was known about the development of the ENS in 1983 and then summarize some of the major advances in the field since 1983.
- 6 July 2016
- Published by Springer Nature
- Vol. 891, 53-62
ENS Development Research Since 1983: Great Strides but Many Remaining Challenges
The first enteric nervous system (ENS) conference, organized by Marcello Costa and John Furness, was held in Adelaide, Australia in 1983. In this article, we review what was known about the development of the ENS in 1983 and then summarize some of the major advances in the field since 1983.
- Open Access
- 9 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (27) , 41186-41202
Identifying and targeting determinants of melanoma cellular invasion
Identifying and targeting determinants of melanoma cellular invasion
- 9 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (27) , 41186-41202
Open AccessIdentifying and targeting determinants of melanoma cellular invasion
Identifying and targeting determinants of melanoma cellular invasion